Skip to main content
Premium Trial:

Request an Annual Quote

Fluidic Analytics: Joe Keegan

Fluidic Analytics has appointed Joe Keegan as the firm's chairman. Keegan currently serves on the boards of Bio-Techne and Interpace Diagnostics, as well as a number of early- and growth-stage companies in the life sciences tools and diagnostic industries. Prior to Fluidic Analytics, Keegan served as CEO as ForteBio until it was sold to Pall Corporation. Before ForteBio, Keegan was CEO of Molecular Devices. Keegan has also held the role of chairman of the Analytical Life Science & Diagnostics Association, non-executive chairman of Labcyte, and non-executive director of Advanced Cellular Diagnostics, ProteinSimple, and Seahorse Bioscience.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.